Protein extracts of Crassostrea gigas alleviate CCl4-induced hepatic fibrosis in rats by reducing the expression of CTGF, TGF-β1 and NF-κB in liver tissues

Zhou,Jue; Liang,Yi; Pan,Jie‑Xue; Wang,Fang‑Fang; Lin,Xian‑Ming; Ma,Rui‑Jie; Qu,Fan; Fang,Jian‑Qiao

doi:10.3892/mmr.2014.3019

Protein extracts of Crassostrea gigas alleviate CCl4-induced hepatic fibrosis in rats by reducing the expression of CTGF, TGF-β1 and NF-κB in liver tissues

Authors:
- Jue Zhou
- Yi Liang
- Jie‑Xue Pan
- Fang‑Fang Wang
- Xian‑Ming Lin
- Rui‑Jie Ma
- Fan Qu
- Jian‑Qiao Fang
View Affiliations

Affiliations: College of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou, Zhejiang 310012, P.R. China, Acupuncture Department, The Third Clinical College of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang 310035, P.R. China, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China
Published online on: November 28, 2014 https://doi.org/10.3892/mmr.2014.3019
Pages: 2913-2920

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatic fibrosis may contribute to liver carcinoma and the mortality of patients with hepatic fibrosis is gradually increasing. However, no definitive treatment has been established for hepatic fibrosis. The hepatic fibrotic process is reversible and can be controlled; therefore, the creation of novel and effective therapeutic methods to prevent or reverse the disease is required. The aim of the present study was to identify whether protein extracts from Pacific oysters (PEPO) could alleviate the hepatic fibrosis induced by CCl4 and to examine the mechanisms involved. A total of sixty rats were randomly divided into the following experimental groups: The normal control group; the hepatic fibrosis model group; the high‑dose; medium‑dose; and low‑dose PEPO groups; and the colchicine group. The results indicated that compared with those of the model group, PEPO treatment significantly decreased the serum levels of alanine aminotransferase, aspartate aminotransferase, γ‑glutamyltransferase, alkaline phosphatase, hyaluronic acid, laminin, collagen type IV and procollagen III in rats with hepatic fibrosis. The hematoxylin and eosin staining demonstrated that PEPO markedly alleviated hepatic fibrosis. The experiments using immunohistochemistry, western blotting and quantitative PCR indicated that protein and mRNA expression levels of connective tissue growth factor (CTGF), transforming growth factor β1 (TGFβ‑1) and nuclear factor κB (NF‑κB) in the liver tissues were significantly reduced by PEPO treatment. Therefore, it was concluded that PEPO successfully alleviated hepatic fibrosis induced by CCl4 and reversed the effects of hepatotoxicity by regulating the serum levels of enzymes and decreasing the expression levels of CTGF, TGF‑β1 and NF‑κB in liver tissues. These findings may provide a novel treatment option for patients with hepatic fibrosis in the future.

View Figures

View References

1	Friedman SL: Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol. 1:98–105. 2004. View Article : Google Scholar
2	Bataller R and Brenner DA: Liver fibrosis. J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI
3	Poli G: Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med. 21:49–98. 2000. View Article : Google Scholar : PubMed/NCBI
4	Afdhal NH: The natural history of hepatitis C. Semin Liver Dis. 24(Suppl 2): 3–8. 2004. View Article : Google Scholar : PubMed/NCBI
5	McMahon BJ: The natural history of chronic hepatitis B virus infection. Semin Liver Dis. 24(Suppl 1): 17–21. 2004. View Article : Google Scholar : PubMed/NCBI
6	Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 11:97–107. 2004. View Article : Google Scholar : PubMed/NCBI
7	Brenner DA: Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc. 120:361–368. 2009.PubMed/NCBI
8	Rosenbloom J, Castro SV and Jimenez SA: Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med. 152:159–166. 2010. View Article : Google Scholar : PubMed/NCBI
9	Lissoos TW, Beno DW and Davis BH: Hepatic fibrogenesis and its modulation by growth factors. J Pediatr Gastroenterol Nutr. 15:225–231. 1992. View Article : Google Scholar : PubMed/NCBI
10	Friedman SL: Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis Mechanisms and treatment strategies. N Engl J Med. 328:1828–1835. 1993. View Article : Google Scholar : PubMed/NCBI
11	Mavier P and Mallat A: Perspectives in the treatment of liver fibrosis. J Hepatol. 22(Suppl): 111–115. 1995.PubMed/NCBI
12	Iredale J: Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacol Res. 58:129–136. 2008. View Article : Google Scholar : PubMed/NCBI
13	Yamaura K, Takahashi KG and Suzuki T: Identification and tissue expression analysis of C-type lectin and galectin in the Pacific oyster, Crassostrea gigas. Comp Biochem Physiol B Biochem Mol Biol. 149:168–175. 2008. View Article : Google Scholar
14	Fishery and Aquaculture Statistics 2007. Food and Agriculture Organization of the United Nations; Rome: pp. 542009
15	Gaté L, Schultz M, Walsh E, et al: Impact of dietary supplement of Crassostrea gigas extract (JCOE) on glutathione levels and glutathione S-transferase activity in rat tissues. In Vivo. 12:299–303. 1998.PubMed/NCBI
16	Gaté L, Paul J, Ba GN, Tew KD and Tapiero H: Oxidative stress induced in pathologies: the role of antioxidants. Biomed Pharmacother. 53:169–180. 1999. View Article : Google Scholar : PubMed/NCBI
17	Gressner OA and Gressner AM: Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int. 28:1065–1079. 2008. View Article : Google Scholar : PubMed/NCBI
18	Tamatani T, Kobayashi H, Tezuka K, et al: Establishment of the enzyme-linked immunosorbent assay for connective tissue growth factor (CTGF) and its detection in the sera of biliary atresia. Biochem Biophys Res Commun. 251:748–752. 1998. View Article : Google Scholar : PubMed/NCBI
19	Zhang D, Wang NY, Yang CB, et al: The clinical value of serum connective tissue growth factor in the assessment of liver fibrosis. Dig Dis Sci. 55:767–774. 2010. View Article : Google Scholar
20	Guo-Qiu W, Nai-Feng L, Xiao-Bo V, et al: The level of connective tissue growth factor in sera of patients with hepatitis B virus strongly correlates with stage of hepatic fibrosis. Viral Immunol. 23:71–78. 2010. View Article : Google Scholar : PubMed/NCBI
21	Piao RL, Brigstock DR, Zhu J, Zhang ML and Gao RP: Clinical significance of connective tissue growth factor in hepatitis B virus-induced hepatic fibrosis. World J Gastroenterol. 18:2280–2286. 2012. View Article : Google Scholar : PubMed/NCBI
22	Dessein A, Arnaud V, He H, et al: Genetic analysis of human predisposition to hepatosplenic disease caused by schistosomes reveals the crucial role of connective tissue growth factor in rapid progression to severe hepatic fibrosis. Pathol Biol (Paris). 61:3–10. 2013. View Article : Google Scholar
23	Torre F, Bellis L, Delfino A, et al: Peripheral blood serum markers for apoptosis and liver fibrosis: are they trustworthy indicators of liver realness? Dig Liver Dis. 40:441–445. 2008. View Article : Google Scholar : PubMed/NCBI
24	Papa S, Zazzeroni F, Bubici C, et al: Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol. 6:146–153. 2004. View Article : Google Scholar : PubMed/NCBI
25	Fu M, Zhang J, Zhu X, et al: Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J Biol Chem. 276:45888–45894. 2001. View Article : Google Scholar : PubMed/NCBI
26	Chen A and Zheng S: Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-kappaB and ERK signalling. Br J Pharmacol. 153:557–567. 2008. View Article : Google Scholar
27	Sun H, Che QM, Zhao X and Pu XP: Antifibrotic effects of chronic baicalein administration in a CCl₄ liver fibrosis model in rats. Eur J Pharmacol. 631:53–60. 2010. View Article : Google Scholar : PubMed/NCBI
28	Erman F, Balkan J, Cevikbaş U, Koçak-Toker N and Uysal M: Betaine or taurine administration prevents fibrosis and lipid peroxidation induced by rat liver by ethanol plus carbon tetrachloride intoxication. Amino Acids. 27:199–205. 2004. View Article : Google Scholar : PubMed/NCBI
29	Lin X, Zhang S, Huang Q, et al: Protective effect of Fufang-Liu-Yue-Qing, a traditional Chinese herbal formula, on CCl₄ induced liver fibrosis in rats. J Ethnopharmacol. 142:548–556. 2012. View Article : Google Scholar : PubMed/NCBI
30	Basu S: Carbon tetrachloride-induced lipid peroxidation: eicosanoid formation and their regulation by antioxidant nutrients. Toxicology. 189:113–127. 2003. View Article : Google Scholar : PubMed/NCBI
31	Oh WY, Pyo S, Lee KR, et al: Effect of Holotrichia diomphalia larvae on liver fibrosis and hepatotoxicity in rats. J Ethnopharmacol. 87:175–180. 2003. View Article : Google Scholar : PubMed/NCBI
32	Dendooven A, Gerritsen KG, Nguyen TQ, Kok RJ and Goldschmeding R: Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers. 16:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
33	Abou-Shady M, Friess H, Zimmermann A, et al: Connective tissue growth factor in human liver cirrhosis. Liver. 20:296–304. 2000. View Article : Google Scholar : PubMed/NCBI
34	Hora C, Negro F, Leandro G, et al: Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver Int. 28:370–376. 2008. View Article : Google Scholar
35	Williams EJ, Gaça MD, Brigstock DR, Arthur MJ and Benyon RC: Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol. 32:754–761. 2000. View Article : Google Scholar : PubMed/NCBI
36	Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 275:2247–2250. 2000. View Article : Google Scholar : PubMed/NCBI
37	Liu Y, Wen XM, Lui EL, et al: Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258. Lab Invest. 89:1152–1160. 2009. View Article : Google Scholar : PubMed/NCBI
38	Gressner OA, Lahme B, Demirci I, Gressner AM and Weiskirchen R: Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol. 47:699–710. 2007. View Article : Google Scholar : PubMed/NCBI
39	Hernandez-Gea V and Friedman SL: Pathogenesis of liver fibrosis. Annu Rev Pathol. 6:425–456. 2011. View Article : Google Scholar
40	Biernacka A, Dobaczewski M and Frangogiannis NG: TGF-β signaling in fibrosis. Growth Factors. 29:196–202. 2011. View Article : Google Scholar : PubMed/NCBI
41	Nakamura T, Sakata R, Ueno T, Sata M and Ueno H: Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology. 32:247–255. 2000. View Article : Google Scholar : PubMed/NCBI
42	Povero D, Busletta C, Novo E, et al: Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol. 25:1075–1091. 2010.PubMed/NCBI
43	Tache D, Bogdan F, Pisoschi C, et al: Evidence for the involvement of TGF-β1-CTGF axis in liver fibrogenesis secondary to hepatic viral infection. Rom J Morphol Embryol. 52(Suppl): 409–412. 2011.
44	Weng HL, Ciuclan L, Liu Y, et al: Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology. 46:1257–1270. 2007. View Article : Google Scholar : PubMed/NCBI
45	Kovalenko E, Tacke F, Gressner OA, et al: Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat. 16:612–620. 2009. View Article : Google Scholar : PubMed/NCBI
46	Igarashi A, Okochi H, Bradham DM and Grotendorst GR: Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell. 4:637–645. 1993. View Article : Google Scholar : PubMed/NCBI
47	Fox ES, Kim JC and Tracy TF: NF-kappaB activation and modulation in hepatic macrophages during cholestatic injury. J Surg Res. 72:129–134. 1997. View Article : Google Scholar : PubMed/NCBI
48	Demirbilek S, Akin M, Gürünlüoğlu K, et al: The NF-kappaB inhibitors attenuate hepatic injury in bile duct ligated rats. Pediatr Surg Int. 22:655–663. 2006. View Article : Google Scholar : PubMed/NCBI
49	Rippe RA, Schrum LW, Stefanovic B, Solís-Herruzo JA and Brenner DA: NF-kappaB inhibits expression of the alpha1(I) collagen gene. DNA Cell Biol. 18:751–761. 1999. View Article : Google Scholar : PubMed/NCBI